Detalhe da pesquisa
1.
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Clin Pharmacokinet
; 62(10): 1445-1459, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603217
2.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Lancet Child Adolesc Health
; 7(10): 718-727, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37562418